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Background: Prevalence and incidence of diabetes and other common comorbid conditions (hypertension,
coronary heart disease, renal disease and chronic lung disease) are extremely high among Indigenous Australians.
Recent measures to improve quality of preventive care in Indigenous community settings, while apparently
successful at increasing screening and routine check-up rates, have shown only modest or little improvements in
appropriate care such as the introduction of insulin and other scaled-up drug regimens in line with evidence-based
guidelines, together with support for risk factor reduction. A new strategy is required to ensure high quality
integrated family-centred care is available locally, with continuity and cultural safety, by community-based care
coordinators with appropriate system supports.
Methods/design: The trial design is open parallel cluster randomised controlled trial. The objective of this
pragmatic trial is to test the effectiveness of a model of health service delivery that facilitates integrated
community-based, intensive chronic condition management, compared with usual care, in rural and remote
Indigenous primary health care services in north Queensland. Participants are Indigenous adults (aged 18–65 years)
with poorly controlled diabetes (HbA1c>=8.5) and at least one other chronic condition. The intervention is to
employ an Indigenous Health Worker to case manage the care of a maximum caseload of 30 participants. The
Indigenous Health Workers receive intensive clinical training initially, and throughout the study, to ensure they are
competent to coordinate care for people with chronic conditions. The Indigenous Health Workers, supported by
the local primary health care (PHC) team and an Indigenous Clinical Support Team, will manage care, including
coordinating access to multidisciplinary team care based on best practice standards. Allocation by cluster to the
intervention and control groups is by simple randomisation after participant enrolment. Participants in the control
group will receive usual care, and will be wait-listed to receive a revised model of the intervention informed by the
data analysis. The primary outcome is reduction in HbA1c measured at 18 months. Implementation fidelity will be
monitored and a qualitative investigation (methods to be determined) will aim to identify elements of the model
which may influence health outcomes for Indigenous people with chronic conditions.
(Continued on next page)* Correspondence: barbara.schmidt@unisa.edu.au
1Getting Better at Chronic Care Project, University of South Australia, School
of Health Sciences, Cairns Diabetes Centre, 381 Sheridan St, North Cairns,
QLD 4870, Australia
Full list of author information is available at the end of the article
© 2012 Schmidt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Schmidt et al. BMC Public Health 2012, 12:1017 Page 2 of 8
http://www.biomedcentral.com/1471-2458/12/1017(Continued from previous page)
Discussion: This pragmatic trial will test a culturally-sound family-centred model of care with supported case
management by IHWs to improve outcomes for people with complex chronic care needs. This trial is now in the
intervention phase.
Trial registration: Australian New Zealand Clinical Trials Registry ACTR12610000812099
Keywords: Aboriginal and Torres Strait Islander, Diabetes, Indigenous Health Worker, Partnerships, HbA1c controlBackground
Prevalence and incidence of Type 2 diabetes mellitus
(T2DM) and other common comorbid conditions
(hypertension, coronary heart disease (CHD), chronic
kidney disease (CKD) and chronic obstructive pulmon-
ary disease (COPD) are extremely high among Indigen-
ous Australians. Cardiovascular and other complications
which can be prevented with good quality primary care
remain 4–7 times higher than for the general population
[1]. This reflects lower access to appropriate and effect-
ive preventive care, as well as ongoing poor nutrition,
life-course exposures and high rates of tobacco exposure
[1]. Vos and colleagues [1] estimate the Indigenous life
expectancy gap at 13 years, and 59% of the total burden
of disease as preventable. Most of this excess is due to
chronic conditions in adults, mainly cardiovascular dis-
ease (CVD), diabetes, mental disorders and chronic lung
disease [1]. Rates for preventable hospitalisations are
more than double in remote and very remote communi-
ties compared with major cities [2].
There is strong evidence, including from the United
Kingdom Prospective Diabetes Study (UKPDS) [3], that
the main goal in treating T2DM should be to achieve
blood glucose levels as close as possible to the non-
diabetic range to prevent chronic microvascular and
macrovascular complications, especially nephropathy.
This evidence is recognised by key national bodies, such
as the Australian Diabetes Society [4] and the American
Diabetes Association [5], which recommend a glycated
haemoglobin (HbA1c) target of <7.0% for most adults
with diabetes. The progressive nature of T2DM means
that many people need intensification of drug therapy
over time if this target is to be achieved. For example,
projections from UKPDS data indicate that most
patients will need insulin therapy to maintain HbA1c
<7.0% after 9 years of diagnosed T2DM [6]. In addition,
the appropriate use of medicines, including angiotensin
converting enzyme inhibitors (ACEI) to protect the kid-
neys and heart, reduces all-cause and CVD-specific mor-
tality as well as progression to end-stage renal disease
[7]. Good management of kidney disease and its attend-
ant cardiovascular risk requires: active stepped care with
renin-angiotensin system blockade (ACEI or angiotensin
receptor blockers, ARB); diuretics, calcium channel
blockers and other drugs to achieve blood pressuregoals; and attempts to back-titrate albuminuria/protein-
uria, with ACEI or ARB [8]. Good management of CVD
in this population with high levels of other conditions
may require five classes of drugs including beta blockers,
antiplatelet agents, ACEI/ARB, statins and nitrates, as
well as good support for smoking cessation, better nutri-
tion and physical activity [8]. In many cases, current care
falls well below these standards. Family engagement is
critical to achieving this for individuals, and in remote
Indigenous communities we believe Indigenous Health
Workers (IHWs) are best placed to deliver this “pack-
age” in a way which is acceptable and understandable
for clients [9].
Recent measures to improve quality of preventive care
in Indigenous community settings, while apparently suc-
cessful at increasing screening and routine check-up
rates (mainly performed by nurses and IHWs) [10], have
shown only modest or little improvements in appropri-
ate doctor-initiated care, specifically the introduction of
insulin and other scaled up drug regimens in line with
evidence-based guidelines [11]. Where improvements
have been demonstrated, the longer term sustainability
of these has been less than hoped, due to, inter alia, fail-
ure of integration of these systems into ongoing service
delivery models and especially of the up-skilling of the
Indigenous workforce with appropriate system-level sup-
port [11]. A similar experience has been reported in the
Indian Health Service in the USA, where “data alone are
not sufficient to effect change. Use of the measures to
ensure that the quality of care improves must also be
stressed, because measuring alone will not guarantee
such improvement” [12]. Although multidisciplinary
support for chronic care is the rule in mainstream set-
tings, this suite of allied health services is not routinely
available to many rural and remote populations, nor are
doctors and nurses trained to deliver these services. Ef-
fective communication between health care workers and
clients is central to good quality chronic care, especially
in populations with low health literacy. A study of
people with diabetes with low health literacy showed
that an HbA1c of <8.6% was up to nine times more
likely when physicians used an interactive educational
strategy assessing comprehension of new concepts [9].
A trial of health worker-delivered diabetes care in the
Torres Strait in 2000 demonstrated that much of this
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by local Indigenous health workers who were close to
the client group linguistically and culturally and pro-
vided greater continuity of care than itinerant, often in-
experienced non-Indigenous health staff [13]. Follow-up
after three years showed sustained improvements in ser-
vice delivery and intermediate clinical outcomes (blood
pressure, glycaemia and complications of diabetes) dem-
onstrating that system-level support for this model could
produce ongoing clinical gains [14] and also be highly
cost-effective [15].
Similarly, a treatment program to modify renal and
cardiovascular disease progression in an Aboriginal
community in the Northern Territory (NT), which con-
centrated on improved drug management of hyperten-
sion and renal disease, showed statistically significant
protection against dialysis and natural death over a
3 year period [16] and also demonstrated high cost-
effectiveness [17]. An outreach program in the NT and
Western Australia showed an increase in prescribed
measurements when screening was regularised and deci-
sion algorithms were established and supported [18].
These programs and others show that Indigenous people
can participate enthusiastically in chronic condition
management, with improvement in clinical profiles, pre-
ventable hospitalisations and mortality.
It is our view that Indigenous health care workers in
many rural and remote communities remain underuti-
lised in chronic care, especially where cultural safety and
dialogue with the extended family is key to better
medium- and long-term management. This presents an
opportunity to improve health care standards in high
need populations. A recent review of progress in dia-
betes and renal care in the Torres Strait showed that,
while clinical registers showed a doubling of the diabetes
caseload in five years, there was little shift in intermedi-
ate clinical indicators [19], reflecting a stalling in doctor-
initiated care, including insulin management and self-
monitoring of blood glucose. At the same time, numbers
of clients on renal care plans have increased markedly,
potentially overwhelming existing dialysis services in the
region [20].
Great disparities remain between reported glycaemia
in Indigenous people compared with the general Austra-
lian population of people with diabetes, where 38%
achieved an HbA1c level of less than 7% compared to
26% or less among Indigenous adults with diabetes [19].
This was reflected in low rates of self-monitoring (4% vs
58%) and insulin treatment (10.5% vs 34.4%), and very
different albuminuria prevalence (34.4% vs 7%) for Abo-
riginal and non-Aboriginal adults with diabetes respect-
ively [21]
This problem of suboptimal primary level preventive
care for chronic conditions is also documented inmainstream clinical settings, where apparent “clinical in-
ertia” by doctors results in suboptimal blood pressure,
lipid and glycaemic control. Over a decade ago the
UKPDS report demonstrated that glycaemia was an im-
portant driver of microvascular complications in dia-
betes, and that chronic complications, especially
nephropathy, could be reduced by 38% for each 1% de-
crease in HbA1c achieved [22]. Yet suboptimal uptake of
relatively simple clinical protocols is still highly preva-
lent [23]. Diabetes is now the single greatest and grow-
ing cause of renal failure requiring dialysis globally. It is
becoming clear that the rate of growth of the traditional
professional health workforce, and the system-level sup-
port behind it, is insufficient to deal effectively with the
current rise in chronic conditions.
For existing and future underserved populations, with
growing needs for quality evidence-based care and with
high rates of comorbid conditions, a new strategy is
required. This new approach must deliver high quality
integrated family-centred care locally, with continuity
and cultural safety, by community-based professionals
and with appropriate system support. Because of this,
our approach is based on a different model of care. A
“family-centred” approach has been developed in con-
sultation with Cape York Aboriginal communities and
Indigenous health workers to implement health reform
in Cape York and is based on several evidence based
programs. It aims to proactively address chronic condi-
tions at both family and individual level and embed a
family-centred approach into the service delivery sys-
tems approach to provide more effective and culturally
safe health service delivery that is sustainable in the
longer term [24]. Glasgow (2003) argues that successful
translation of research into practice in chronic care
requires methods that will:
1. “enhance and measure the reach of the interventions,
especially toward poor, undeserved and minority
populations;
2. develop programs that can be adopted in diverse
settings;
3. produce replicable effects and enhance quality of life,
in addition to short term behavioural or biological
outcomes;
4. be consistently implemented by different staff
members having moderate levels of training; and
5. produce maintenance at both individual and setting
levels at reasonable cost” [25].
This trial forms part of a broader project that aims to
introduce and evaluate a new strategy for integrated
community-based, intensive chronic condition manage-
ment in rural and remote Indigenous primary care ser-
vices in north Queensland.
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1. A randomised controlled trial of intensive locally-
delivered chronic care in 12 participating sites in Far
North Queensland, with clinical and quality of life
outcomes. A cluster randomised control design has
been used to avoid contamination bias in results that
may arise from control and intervention participants
being in the same community [26].
2. Review of the model in the light of the trial
results, discussions about generalisability and
associated process evaluation and qualitative
enquiries, with development of an implementation
plan (encompassing potential regional implications
of a family-centred service delivery model,
including workforce and funding applications)
and the refinement of the project training
program.Figure 1 Flowchart for a cluster randomised controlled trial of family3. In collaboration with the trial partners (Queensland
Health, Apunipima Cape York Health Council and
local Aboriginal Medical Services) implementation of
the revised model will occur in the wait listed
communities.
Ethics approval of the protocol was granted in Novem-
ber 2010.
Method/design
A project flow diagram illustrating the research design is
shown in Figure 1.
Participants
The setting for the study is 12 primary health care ser-
vices located in 12 rural north Queensland communities
which have a significant Indigenous population, and
where the service is provided either by Queensland-centred chronic care delivered by IHWs to Indigenous clients.
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Health Service.
The project was initiated by University of South Australia
in partnership with Queensland Health, Apunipima Cape
York Health Council and the University of Queensland in
July 2010. The decisions about which communities to ap-
proach to be involved in the study was made in consult-
ation with the key service delivery partners. Involving the
partners was a key strategy to ensure communities selected
had the service capacity and organisational support to be
involved in the project.
Participants in the study are Aboriginal and Torres
Strait Islander people diagnosed at least one year prior
to recruitment with T2DM with HbA1c ≥8.5%, plus at
least one of either COPD, CHD, CKD (Stages 1 to 3), or
hypertension.
The exclusion criteria are:
 People aged > 65 years;
 Children and/or young people (<18 years);
 People with an intellectual or mental impairment
(people with major mental illness);
 Women who are pregnant;
 CKD Stages 4 & 5.
These participants are clustered by health service.Table 1 Standardised and Contextualised elements of the int
Standardised elements
Family-centred
case
management by
IHW
• Qualifications of HW (min Certificate IV in Aboriginal an
Torres Strait Islander Primary Health Care)
• Caseload 1.0 FTE:15-30 clients
• IHW supernumerary to primary health care team
• Training & orientation program (72 hrs face-to-face):
Competency-based training in primary, secondary and te
health promotion interventions and clinical managemen
diabetes and COPD, CKD (Stages 1-3), hypertension and
• Supervisors attend orientation workshop
• 6-monthly training (one week)
• Chronic Disease Guidelines (2010) as clinical governanc
protocol
• COPD screening with Piko 6 spirometer
System Support • Trial manager
• 2 FTE ICST for 6 HWs
• Weekly report and plan
• Weekly meeting (phone or video)
• Remote clinical supervision of caseload
• Monthly IHW meeting by videoconferenceIntervention
One IHW full time equivalent (FTE) who is eligible at
IHW Level 004 [27] will be recruited for each cluster
(maximum 30 participants) in the intervention group,
The role of the IHW is to coordinate the care of partici-
pants in their community.
As this is a pragmatic trial, there are both standardised
and contextualised elements of the intervention, which
are listed in Table 1.
An Indigenous Clinical Support Team (ICST) that
consists of a registered nurse (s) and IHW will train and
mentor the community-based IHWs to coordinate in-
tensive management for five common chronic condi-
tions, according to the clinical and service goals outlined
in the Chronic Disease Strategy [28]. Specific training
and support will be provided for:
 Evidence-based management and treatment goals in
T2DM, hypertension, COPD, CKD and CHD.
 Hands-on case management of individuals.
 Working in PHC team, with clear roles and
responsibilities of team members.
 Engaging with participants’ families and using local
resources to support effective self-management.ervention
Contextualised elements
d • use local PHC information systems
• use local referral pathways
• use local care planning templates
rtiary
t of
CHD
• use local education resources
• Level and nature of contact with clients is at IHW’s discretion:
ie they determine the appropriate language, resources,
frequency and setting for care and education (home visits etc)
according to client needs
e
• Weekly support uses reflective practice technique, responding
to the needs and context of each HW
• Problem solving for local context, eg working with local team
to establish/facilitate care plan process, sorting contract issues
etc
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care. Data analysis and discussion will inform a revised
intervention, which will then be provided to participants
in the control (waitlist) group.
Objective
We aim to compare the effectiveness of an integrated,
family-centred and culturally safe model of care, com-
pared with usual care, for improving tertiary preventive
care for clusters of Indigenous people with complex
chronic care needs.
Outcomes
The primary outcome is reduction in HbA1c measured
at 18 months. The secondary outcomes to be measured
at the cluster level are:
 clinical care processes (initiation of self-monitoring
of blood glucose, introduction of insulin for those
with HbA1c>9%, appropriate use of ACEI/ARBs,
aspirin, beta-blockers, statins, oral hypoglycaemic
agents, agents for COPD and lung function
monitoring)
 intermediate condition-specific outcomes
(progression of estimated glomerular filtration rate,
albumin creatinine ratio, blood pressure, lipids);
 avoidable hospitalisations;
 mortality;
 quality of life scores.
Process evaluation
Factors relating to the delivery of the intervention will
be documented and analysed. Key areas for evaluation
include the:
 development and review of training materials and
curriculum;
 interviews with IHWs and clients exploring the
nature and continuity of the relationship between
IHW and client; and
 extent of contact with clients and their families by
IHWs.
Sample size
The trial is powered to demonstrate a reduction in mean
HbA1c by 1.0% over 18 months in the intervention
group compared to the control group. This estimate is
based on a mean drop of 1.3% HbA1c over one year
(from 9.9% to 8.6%, following initiation of intensive drug
treatment in T2DM) reported by a large US Health
Maintenance Organisation [29]. A sample size of 49 in
each group will have 90% power to detect a difference in
mean HbA1c between the intervention and control
group after 18 months of 1.0%, assuming that thecommon standard deviation is 1.5% using a two group t-
test with a 0.050 two sided significance level. With 12
communities (six intervention, six control), this would
require nine participants per community. However, due
to the intervention being at the level of the health ser-
vice and provider (cluster) rather than individual, the
sample size needs to be inflated by the design effect,
where:
Design effect ¼ 1þ n 1ð Þ ρ
where n is the average cluster number, and ρ the
expected intra-class correlation coefficient for HbA1c.
With n=9 and a ρ of 0.025 [22] the design effect = 1.2.
Hence the required number of participants per commu-
nity is 11 for the primary outcome. However, due to po-
tential difficulty of maintaining participants in these
communities in the trial, the potential for a more mod-
est effect size in this group, and considering the rela-
tively large number of secondary outcomes, we aim to
recruit 30–35 participants in each community.
A second power calculation is based on expected re-
duction in avoidable hospitalisations in the intervention
sites, related to the main chronic conditions. The esti-
mated effect size is 0.08, based on the impact of the
Torres Trial where an absolute reduction of 8% was
achieved in the intervention sites over 12 months, and
people with diabetes there were 40% less likely to be
hospitalised with a diabetes-related complication com-
pared to controls (RR=0.4) [9]. Thus, assuming a similar
effect size, a two group Chi-square test with a 0.050
two-sided significance level will have 90% power to de-
tect a difference in absolute reduction in avoidable hos-
pitalisations of 8%, when the sample size in each arm is
125. Again, allowing for a design effect of 1.2, this would
require 150 participants in each treatment arm.Randomisation
Clusters were allocated to the intervention or waitlist
groups using a simple randomisation method of pulling
community names from a hat. Participants were enrolled
by a local Indigenous worker nominated by the partici-
pating service. Allocation was concealed because clusters
were randomly assigned to the intervention group after
enrolment of participants. There is no masking of parti-
cipants, IHWs or the research team.Statistical methods
The primary statistical analysis will be by intention-to-
treat, using generalised linear mixed effects models, tak-
ing into account clustering by community.
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Improving Indigenous health and chronic disease manage-
ment have been identified nationally and in Queensland as
priority areas for investment by policy makers and fund-
ing agencies [30,31]. The rural and remote Indigenous
health service delivery environment in north Queens-
land is characterised by high turnover of medical, nurs-
ing and allied health staff and specialist fly-in-fly-out
services, hindering the systematic approach to service
delivery required to effectively manage client care. Indi-
genous people often require additional support to access
the health system, engagement with families to find ef-
fective solutions to health problems and better commu-
nication to understand the care or medications being
prescribed to them [32]. To address these issues, efforts
are required to enable, train, and encourage Indigenous
people to take responsibility for programs and services
that affect their health and for them to work closely
with existing health-care systems [32].
This pragmatic trial will test a culturally-sound family-
centred model of care with supported case management
by IHWs to improve outcomes for people with complex
chronic care needs. Its strong design ensures that the
results will provide high quality evidence of the impact
of such a model on meaningful outcomes. Other studies
evaluating chronic care interventions have found that
outcomes across communities can be variable [33].
Reports of pragmatic trials need to provide sufficient
details about the setting, participants and intervention
for users to determine if the results are generalisable to
their own situation [34]. To this end, monitoring the fi-
delity of implementation to the model will be a key char-
acteristic of the study [35].
This trial is now in the intervention phase. We expect
to report on early lessons learnt from the planning and
implementation of this trial shortly.
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